For more than two decades, we've all benefited from your outstanding financial leadership, your thoughtful guidance, and trusted partnership. Strong growth in our bioprocessing business, paired with disciplined cost management, enabled us to exceed both our adjusted operating profit margin and cash flow expectations for the quarter. Academic and government demand remained soft as expected, with ongoing uncertainty around research funding. We're well-positioned in attractive end markets, driven largely by non-discretionary healthcare needs and supported by strong secular growth drivers.
On top of this, our strong balance sheet and free cash flow generation positions us well to further enhance our portfolio going forward. Sales were $5.9 billion in the second quarter, and we delivered 1.5% core revenue growth. Geographically, core revenues in developed markets were up low single-digits, with North America up slightly and a high single-digit increase in Western Europe. Core revenues in high-growth markets were flat overall, as solid performance outside of China was offset by a mid-single-digit decline in China.
Growth in our biotechnology and life sciences businesses in China was more than offset by declines in diagnostics due to volume-based procurement and reimbursement changes implemented in late 2024. Our adjusted operating profit margin of 27.3% was flat year-over-year as the favorable impacts of higher volume leverage, product mix, and disciplined cost management were offset by productivity investments to reduce our structural costs. Adjusted diluted net earnings per common share of $1.80 were up approximately 5% year-over-year. We generated $1.1 billion of free cash flow in the quarter and $2.2 billion in the first half of the year, resulting in a year-to-date free cash flow-to-net income conversion ratio of 143%.
| Metric | Period | Current guidance |
|---|---|---|
| Adjusted diluted EPS (full year) | FY2025 | high end ~$7.80 (Raised ~$0.20 for cost actions and better first-half FX) |
| Bioprocessing revenue growth | FY2025 | high single-digit (Maintained) |
| Bioprocessing core growth | 2H2025 (Q3 and Q4) | high single-digit (Reaffirmed) |
| Life sciences segment growth | FY2025 | flat full year (2H up low single-digit) (~$150M step-up 1H to 2H) |
| Respiratory revenue | FY2025 | $1.7 billion (Maintained (tracking slightly north of $900M in 1H)) |
| Structural cost-out savings | FY2025 | $150 million (Reaffirmed; about half achieved) |
| Tariff cost exposure | FY2025 | ~couple hundred million (Lowered; company plans to offset all tariffs paid) |
| Metric | YoY | Note |
|---|---|---|
| Core revenue | +1.5% | Solid execution despite a dynamic operating environment; developed markets up low single-digits, high-growth markets flat. |
| Developed markets core revenue | up low single-digits | North America up slightly and Western Europe up high single-digits. |
| High-growth markets core revenue | flat | Solid performance outside China offset by a mid-single-digit decline in China. |
| China core revenue | down mid-single-digit | Biotech and life sciences growth more than offset by diagnostics declines from volume-based procurement and reimbursement changes implemented in late 2024. |
| Bioprocessing consumables | low double-digit growth | Commercial demand and large pharma and CDMO customers; smaller customers stable but below historical levels. |
| Adjusted operating profit margin | flat at 27.3% | Favorable volume leverage, product mix, and disciplined cost management offset by productivity investments to reduce structural costs. |
| Adjusted diluted EPS | +~5% to $1.80 | Higher volume, mix, and cost management. |
| Cepheid non-respiratory reagents | low double-digit growth | Installed base expansion at large IDNs and menu adoption across sexual health, virology, and hospital-acquired infections. |
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Bioprocessing recovery and book-to-bill | seventh consecutive quarter of book-to-bill solidly over one (Q1) | book-to-bill around one with lumpiness in equipment orders; consumables strong | Steady |
| Global trade tensions and tariffs | ~$350 million tariff exposure | ~couple hundred million exposure; net neutral in China; pharma capacity decisions delayed | Declining (exposure lower) but persistent uncertainty |
| China diagnostics volume-based procurement | $150 million expected 2025 impact | $150 million impact unchanged; volumes consistent with Q1 | Steady |
| Bioprocessing equipment demand | below historical trends | still below historical trends; funnels improving but order decisions delayed | Steady (down year expected for 2025) |
| China outside diagnostics | — | firming up with slight bioprocessing growth and stimulus aiding life science tools | Rising |
| Respiratory endemic rate | $1.7 billion guide held for ~3 years | maintained at $1.7 billion; open to revisiting after another year | Steady |
| AI as a tailwind for biotech | — | viewed positively as it shifts spend toward validated, commercialized therapies where Danaher has most volume | Rising |
| CFO succession | — | Matt Gugino to succeed Matt McGrew as CFO at end of February 2026 | Rising |